Uso de levodopa, carbidopa y entacapona para el tratamiento de la enfermedad de Parkinson

J Rouru, M KUOPPAMÄKI, J Ellmen, P MÄNNISTÖ - 2017 - Google Patents
ES2614179T3 - Uso de levodopa, carbidopa y entacapona para el tratamiento de la enfermedad
de Parkinson - Google Patents ES2614179T3 - Uso de levodopa, carbidopa y entacapona para …

[PDF][PDF] 999lo sm. 9

RH VOllendorff - ncbi.nlm.nih.gov
The dosage of EUTONYL should be carefully adjusted As EUTONYL is a Mono-Amine
Oxidase Inhibitor, to the individual patient's response, judged by the patients should be …

[引用][C] Meprobamate-like Agents Bibliographies

M GORDON - Psychopharmacological Agents, 1967 - Elsevier

[引用][C] Meprobamate, a clinical evaluation

NM Dixon - Annals of the New York Academy of Sciences, 1957 - Wiley Online Library
The findings and opinions given in this paper are the result of clinical observations on
consecutive patients seen in a busy medical practice-patients, of course, in whom physical …

Meprobamate addiction

RC Mohr, BT Mead - New England Journal of Medicine, 1958 - Mass Medical Soc
A LITTLE over three and a half years ago, a new medication, meprobamate, was widely
promoted for use in a variety of maladies. There is no doubt of its efficacy as a muscle …

AMA Officials and Executive Staff, 1966-1967

JD Porterfield - jamanetwork.com
Careful supervision of dose and amounts prescribed is advised. Consider possibil¬ ity of
dependence, particularly in patients with history of drug or alcohol addiction; withdraw …

[引用][C] FINDING THE OPTIMUM CARBIDOPA: lEVODOPA COMBINATION FOR PARKINSONISM

WW Tourtellotte - InPharma, 1981 - Springer
In this study 29 patients with Parkinsonism were randomly assigned to one of 3 treatments
using: levodopa IOOmg tablets alone-10 patients; carbidopa I Omg: levodopa I OOmg …

[引用][C] PARKINSON'S DISEASE Levodopa Levodopa (L-dopa) is the metabolic precursor of dopamine and unlike dopamine can cross the blood brain barrier. In the …

GP Mathur, P Dubey, S Mathur - Movement …, 2003 - JAYPEE BROTHERS PUBLISHERS

Benefits of a new galenic form of levodopa and benserazide in the treatment of patients with Parkinson disease

CA Dessibourg, JP Gachoud - Praxis, 1995 - europepmc.org
We describe a new, water-soluble formulation of levodopa plus benserazide (Madopar LIQ)
for the treatment of Parkinson's disease. Two dosage strengths are available: 100 mg …

Effects of levodopa on nondopaminergic brain neurons

RJ Wurtman, JA Romero - Neurology, 1972 - AAN Enterprises
Effects of levodopa on nondopaminergic brain neurons Page 1 Effects of levodopa on
nondopaminergic brain neurons RJ Wurtman, MD, and JA Romero a The therapeutic efficacy of …